Cell Metab (2013) 17:4960
Weissman Z, Shemer R, Kornitzer D
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Only pharmaceutical-grade peptides are fit for human use , as the purity criteria for research-grade materials are generally much less rigorous, partially incomplete, and/or poorly followed, per one study
This four-compound blend is utilised in laboratory research involving peptide interactions, cellular signalling pathways, and complex experimental models